Decreased glucagon-like peptide 1 receptor expression in endothelial and smooth muscle cells in diabetic db/db mice: TCF7L2 is a possible regulator of the vascular glucagon-like peptide 1 receptor

Diabetes and Vascular Disease Research

Volumn 14, Issue 6, 2017, Pages 540-548

  Kimura, Tomohiko ^a   Obata, Atsushi ^a   Shimoda, Masashi ^a   Okauchi, Seizo ^a   Hirukawa, Hidenori ^a   Kohara, Kenji ^a   Kinoshita, Tomoe ^a   Nogami, Yuka ^a   Nakanishi, Shuhei ^a   Mune, Tomoatsu ^a   Kaku, Kohei ^a   Kaneto, Hideaki ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Atherosclerosis; glucagon like peptide 1 receptor; glucolipotoxicity; transcription factor 7 like 2; vascular endothelial cell; vascular smooth muscle cell

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR 7 LIKE 2; GLP1R PROTEIN, MOUSE; TCF7L2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; HUMAN; HUMAN CELL; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REGULATORY MECHANISM; VASCULAR ENDOTHELIAL CELL; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CELL CULTURE; DISEASE MODEL; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; RNA INTERFERENCE; SMOOTH MUSCLE CELL; THORACIC AORTA; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; CELLS, CULTURED; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENDOTHELIAL CELLS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RNA INTERFERENCE; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 85032874682     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164117725898     Document Type: Article

References (16)

1. Koska J., Incretins and preservation of endothelial function. Cardiovasc Hematol Agents Med Chem 2012; 10: 295-308.
2. Holst JJ., The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
3. Richter G, Feddersen O, Wagner U, et al. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 1993; 265: L374-L381.
4. Gaspari T, Liu H, Welungoda I, et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab Vasc Dis Res 2011; 8: 117-124.
5. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-E1215.
6. Mita T, Katakami N, Shiraiwa T, et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE). A randomized controlled trial. Diabetes Care 2016; 39: 455-464.
7. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59: 1030-1037.
8. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322.
9. Xu G, Kaneto H, Laybutt DR, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007; 56: 1551-1558.
10. Kaneto H, Matsuoka TA., Role of pancreatic transcription factors in maintenance of mature beta-cell function. Int J Mol Sci 2015; 16: 6281-6297.
11. Kubota T, Kubota N, Kumagai H, et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011; 13: 294-307.
12. Srivastava R, Zhang J, Go GW, et al. Impaired LRP6-TCF7L2 activity enhances smooth muscle cell plasticity and causes coronary artery disease. Cell Rep 2015; 13: 746-759.
13. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999; 354: 617-621.
14. Kimura T, Kaneto H, Kanda-Kimura Y, et al. Seven-year observational study on the association between glycemic control and the new onset of macroangiopathy in Japanese subjects with type 2 diabetes. Intern Med 2016; 55: 1419-1424.
15. Kaneto H, Katakami N, Kawamori D, et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 2007; 9: 355-366.
16. Kaneto H, Katakami N, Matsuhisa M, et al. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm 2010; 2010: 453892.